NOTCH1 driven metastasis in BRAF mutated colorectal cancer

被引：0
|
作者：
White, M. [1 ]
Tsantoulis, P. [2 ]
Lannagan, T. [1 ]
Najumudeen, A. [1 ]
Ridgeway, R. A. [1 ]
Campbell, A. D. [1 ]
Jackstadt, R. [3 ]
Wilson, R. H. [4 ]
Sansom, O. J. [1 ]
机构：
[1] CRUK Canc Res UK Beatson Inst, Colorectal Canc & Wnt Signalling, Glasgow, Lanark, Scotland
[2] UNIGE Univ Geneva, Fac Med, Dept Internal Med Specialties, Geneva, Switzerland
[3] German Canc Res Ctr, Div Canc Progress & Metastasis, Heidelberg, Germany
[4] Wolfson Wohl Canc Res Ctr, Inst Canc Sci, Glasgow, Lanark, Scotland
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.053
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
26P
引用
收藏
页码：S554 / S554
页数：1
相关论文
共 50 条
  • [31] Classification of BRAF mutated colorectal cancer based on microsatellite stability.
    Nakano, Michitaka
    Sagara, Kosuke
    Koreishi, Sakuya
    Aikawa, Tomomi
    Nishijima, Tomohiro F.
    Takayoshi, Kotoe
    Komoda, Masato
    Baba, Eishi
    Esaki, Taito
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [32] Incidence of venous thromboembolism in patients with BRAF-mutated colorectal cancer
    Ortega Moran, L.
    Pesantez, D.
    Brozos Vazquez, E.
    Fernandez Garay, D.
    Lobo de Mena, M.
    Ribera Fernandez, P.
    Sanchez Canovas, M.
    Salgado, M.
    Garcia Perez, E.
    Iriarte Moncho, E.
    Moron Garcia, B.
    Font, C.
    Gallardo, E.
    Perez Altozano, J.
    Munoz Martin, A.
    THROMBOSIS RESEARCH, 2022, 213 : S20 - S20
  • [33] Immune checkpoint inhibitors in BRAF-mutated advanced colorectal cancer
    Kassab, Rebecca
    Khalil, Michel Abou
    Kassab, Joseph
    Kourie, Hampig Raphael
    FUTURE ONCOLOGY, 2023, 19 (36) : 2417 - 2424
  • [34] Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
    White, M.
    Lannagan, T.
    McGarry, L.
    Carlin, L.
    Mills, M.
    Yazgili, A. S.
    Ridgway, R.
    Jackstadt, R.
    Campbell, A. D.
    Wilson, R. H.
    Sansom, O. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S195 - S195
  • [35] BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
    Romain Cohen
    Pascale Cervera
    Magali Svrcek
    Anna Pellat
    Chantal Dreyer
    Aimery de Gramont
    Thierry André
    Current Treatment Options in Oncology, 2017, 18
  • [36] Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
    Rosati, Gerardo
    Aprile, Giuseppe
    Basile, Debora
    Avallone, Antonio
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [37] BRAF-mutated metastatic colorectal cancer between past and future
    Chiara Cremolini
    Massimo Di Maio
    Fausto Petrelli
    Rosa Berenato
    Fotios Loupakis
    Filippo Pietrantonio
    British Journal of Cancer, 2015, 113 : 1634 - 1635
  • [38] First line therapy in stage IV BRAF mutated colorectal cancer
    Petrelli, Fausto
    Antista, Maria
    Dottorini, Lorenzo
    Russo, Alessandro
    Arru, Marcella
    Invernizzi, Roberta
    Manzoni, Mariangela
    Cremolini, Chiara
    Zaniboni, Alberto
    Garrone, Ornella
    Tomasello, Gianluca
    Ghidini, Michele
    HELIYON, 2024, 10 (17)
  • [39] The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer
    Rustighi, Alessandra
    Tiberi, Luca
    Soldano, Alessia
    Napoli, Marco
    Nuciforo, Paolo
    Rosato, Antonio
    Kaplan, Fred
    Capobianco, Anthony
    Pece, Salvatore
    Di Fiore, Pier Paolo
    Del Sal, Giannino
    NATURE CELL BIOLOGY, 2009, 11 (02) : 133 - U62
  • [40] BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
    Cohen, Romain
    Cervera, Pascale
    Svrcek, Magali
    Pellat, Anna
    Dreyer, Chantal
    de Gramont, Aimery
    Andre, Thierry
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (02)
12345